| Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial.Eur Respir J | PMID 35361630无 PMCID | 2022-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Public engagement during a typhoid conjugate vaccine trial in Lalitpur, Nepal- experience, challenges and lessons learnt.Hum Vaccin Immunother | PMID 35240925PMC9196674 | 2022-Nov-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A multicenter, single-blind, randomized, phase-2/3 study to evaluate immunogenicity and safety of a single intramuscular dose of biological E's Vi-capsular polysaccharide-CRM197 conjugate typhoid vaccine (TyphiBEVTM) in healthy infants, children, and adults in comparison with a licensed comparator.Hum Vaccin Immunother | PMID 35333702PMC9196756 | 2022-Nov-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The eight-year long-term follow-up on the effectiveness of the quadrivalent human papillomavirus vaccine in Chinese women 20-45 years of age.Hum Vaccin Immunother | PMID 35358015PMC9225595 | 2022-Nov-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Comparing the meningococcal serogroup C immune response elicited by a tetanus toxoid conjugate quadrivalent meningococcal vaccine (MenACYW-TT) versus a quadrivalent or monovalent C tetanus toxoid conjugate meningococcal vaccine in healthy meningococcal vaccine-naïve toddlers: A randomised, controlled trial.Hum Vaccin Immunother | PMID 35445641PMC9225511 | 2022-Nov-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and immunogenicity of a quadrivalent, inactivated, split-virion influenza vaccine (IIV4-W) in healthy people aged 3-60 years: a phase III randomized clinical noninferiority trial.Hum Vaccin Immunother | PMID 35714276PMC9621009 | 2022-Nov-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Immunogenicity and safety of a booster dose of the hepatitis B vaccine HepB-CpG (HEPLISAV-B®) compared with HepB-Eng (Engerix-B®) and HepB-AS04 (Fendrix®) in adults receiving hemodialysis who previously received hepatitis B vaccination and are not seroprotected: Results of a randomized, multicenter phase 3 study.Hum Vaccin Immunother | PMID 36269938PMC9746491 | 2022-Nov-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Weekly Somapacitan is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial.J Clin Endocrinol Metab | PMID 36062966PMC9693810 | 2022-Nov-25 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX).J Neurodev Disord | PMID 36434514PMC9700889 | 2022-Nov-25 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and Immunogenicity of V114, a 15-valent Pneumococcal Conjugate Vaccine, Compared with 13-valent Pneumococcal Conjugate Vaccine in Japanese Adults Aged ≥65 Years: Subgroup Analysis of a Randomized Phase III Trial (PNEU-AGE).Jpn J Infect Dis | PMID 35908869无 PMCID | 2022-Nov-22 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Ultrasound-assisted carbon nanoparticle suspension mapping versus dual tracer-guided sentinel lymph node biopsy in patients with early breast cancer (ultraCars): phase III randomized clinical trial.Br J Surg | PMID 36074703PMC10364740 | 2022-Nov-22 | 0.95 | The study is a phase III randomized trial in oncology with human subjects and original results, but it is excluded because the primary endpoint is a diagnostic performance metric (SLN identification rate), not a time-to-event efficacy endpoint. The intervention is a procedural/diagnostic technique, not a drug intervention for treatment efficacy. | 待处理 |
| Safety, tolerability and immunogenicity of Biological E's CORBEVAX™ vaccine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, phase-2/3 study.Vaccine | PMID 36328879无 PMCID | 2022-Nov-22 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study.J Headache Pain | PMID 36404301PMC9676838 | 2022-Nov-21 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial).Blood Cancer J | PMID 36404343PMC9676182 | 2022-Nov-21 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Oxaliplatin (3 months v 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07.J Clin Oncol | PMID 35772045PMC9671755 | 2022-Nov-20 | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trial.BMJ | PMID 36384746PMC9667467 | 2022-Nov-16 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Stereotactic Radiotherapy after Incomplete Transarterial (Chemo-) Embolization (TAE\TACE) versus Exclusive TAE or TACE for Treatment of Inoperable HCC: A Phase III Trial (NCT02323360).Curr Oncol | PMID 36421345PMC9689962 | 2022-Nov-16 | 0.95 | The record is a randomized Phase III oncology trial with human patients and time-to-event efficacy endpoints (local control, PFS, OS). However, the intervention compared is stereotactic body radiotherapy (SBRT) versus transcatheter arterial (chemo-)embolization (TAE/TACE). TACE is a procedure involving embolization and may include chemotherapy, but the trial is fundamentally comparing a radiation technique to an embolization procedure. The abstract does not specify a standardized drug regimen as the intervention; it focuses on the procedural modality. Therefore, it does not meet the requirement for a drug-containing intervention. | 待处理 |
| Immunogenicity and safety of two novel human papillomavirus 4- and 9-valent vaccines in Chinese women aged 20-45 years: A randomized, blinded, controlled with Gardasil (type 6/11/16/18), phase III non-inferiority clinical trial.Vaccine | PMID 36283897无 PMCID | 2022-Nov-15 | 0.85 | The study is a Phase III randomized trial with a drug intervention and is oncology-related (HPV vaccines for cancer prevention). However, the primary endpoint is immunogenicity (seroconversion rates, geometric mean titers), not a time-to-event efficacy endpoint like OS, PFS, DFS, etc. No time-to-event analysis (Kaplan-Meier, hazard ratio) is mentioned in the abstract. | 待处理 |
| Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.J Clin Oncol | PMID 35605174无 PMCID | 2022-Nov-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group.J Clin Oncol | PMID 35709415无 PMCID | 2022-Nov-10 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Pyridostigmine reduces mortality of patients with severe SARS-CoV-2 infection: A phase 2/3 randomized controlled trial.Mol Med | PMID 36348276PMC9644007 | 2022-Nov-08 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Prostate MRI versus PSA screening for prostate cancer detection (the MVP Study): a randomised clinical trial.BMJ Open | PMID 36351725PMC9644313 | 2022-Nov-08 | 0.90 | Study is a randomized, Phase III oncology trial with results, but it compares diagnostic modalities (MRI vs PSA) and lacks a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). | 待处理 |
| Efficacy and safety of miconazole muco-adhesive tablet versus itraconazole in oropharyngeal candidiasis: A randomized, multi-centered, double-blind, phase 3 trial.Med Mycol | PMID 36149321无 PMCID | 2022-Nov-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma.N Engl J Med | PMID 36322844PMC9945772 | 2022-Nov-03 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging.Rheumatology (Oxford) | PMID 35188180PMC9629340 | 2022-Nov-02 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter.Neuro Oncol | PMID 35511454PMC9629431 | 2022-Nov-02 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and Safety of Olanzapine in Children Receiving Highly Emetogenic Chemotherapy: A Randomized, Double-blind Placebo-controlled Phase 3 Trial.J Pediatr Hematol Oncol | PMID 35091522无 PMCID | 2022-Nov-01 | 0.85 | The study is a randomized Phase III trial in oncology patients, but its primary efficacy endpoint is the rate of complete control of vomiting (a categorical outcome), not a time-to-event endpoint such as OS, PFS, or any other survival/metrics typically analyzed with Kaplan-Meier methods or reported with Hazard Ratios. | 待处理 |
| Immunogenicity and safety of a bivalent, adjuvant system 04-adjuvanted human papillomavirus vaccine in healthy female volunteers aged 15-25: a randomized, double-blind, phase III, noninferiority clinical trial.Eur J Cancer Prev | PMID 35352698无 PMCID | 2022-Nov-01 | 0.95 | The study is a Phase III randomized trial of a drug-containing vaccine intervention in an oncology-related context (HPV prevention for cervical cancer). However, the primary efficacy endpoint is noninferiority based on immunogenicity (GMT ratios and seroconversion rates), not a time-to-event outcome such as OS, PFS, DFS, EFS, RFS, TTP, or any analysis using Kaplan-Meier or reporting a hazard ratio. Therefore, it does not meet the required time-to-event efficacy endpoint criterion for this cohort. | 待处理 |
| Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study.J Clin Oncol | PMID 35605188PMC9622589 | 2022-Nov-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated EGFR.J Clin Oncol | PMID 35960896PMC9622660 | 2022-Nov-01 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial.JAMA Oncol | PMID 36048453PMC9437831 | 2022-Nov-01 | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials.JAMA Neurol | PMID 36121669PMC9486635 | 2022-Nov-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and Immunogenicity of Cell-Based Quadrivalent Influenza Vaccine: A Randomized Trial.Pediatrics | PMID 36214072无 PMCID | 2022-Nov-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Calmangafodipir for Prevention of Oxaliplatin-Induced Peripheral Neuropathy: Two Placebo-Controlled, Randomized Phase 3 Studies (POLAR-A/POLAR-M).JNCI Cancer Spectr | PMID 36308441PMC9678401 | 2022-Nov-01 | 0.95 | The study is a randomized, placebo-controlled Phase 3 oncology trial with a drug intervention and reports original primary results. However, the primary endpoint is a binary patient-reported outcome (incidence of moderate-to-severe CIPN at a fixed time point), not a time-to-event efficacy endpoint (such as OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier estimation or hazard ratio. Therefore, it does not meet the time-to-event criterion for inclusion. | 待处理 |
| Quality of life in patients with locally advanced head and neck squamous cell carcinoma undergoing concurrent chemoradiation with once-a-week versus once-every-3-weeks cisplatin.Cancer Med | PMID 35343648PMC9636500 | 2022-Nov | 0.90 | The record is a Phase III randomized trial of a drug-containing intervention in oncology, but the abstract explicitly states the primary endpoint was locoregional control and the focus of this report is the key secondary endpoint of quality of life. It does not report a primary or key secondary time-to-event efficacy endpoint (such as OS, PFS, DFS, etc.) with Kaplan-Meier or HR results. Therefore, it is excluded based on the time_to_event criterion. | 待处理 |
| Subretinal Fluid Resolution and Visual Acuity in Patients with Neovascular Age-Related Macular Degeneration: A HARBOR Post Hoc Analysis.Ophthalmol Retina | PMID 35654363无 PMCID | 2022-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study.Lancet Respir Med | PMID 35662408无 PMCID | 2022-Nov | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Phase II/III Results of a Trial of Anti-Tumor Necrosis Factor Multivalent NANOBODY Compound Ozoralizumab in Patients With Rheumatoid Arthritis.Arthritis Rheumatol | PMID 35729713PMC9828347 | 2022-Nov | 0.95 | The study is a Phase II/III randomized trial of a drug (ozoralizumab) for rheumatoid arthritis, not a human malignant neoplasm. It lacks a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The deterministic review correctly identified the lack of a time-to-event signal and non-oncology context. | 待处理 |
| Meaningful Improvement in General Health Outcomes with Guselkumab Treatment for Psoriatic Arthritis: Patient-Reported Outcomes Measurement Information System-29 Results from a Phase 3 Study.Patient | PMID 35768650PMC9584870 | 2022-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Interpreting Within-Patient Changes on the EORTC QLQ-C30 and EORTC QLQ-LC13.Patient | PMID 35771392PMC9585005 | 2022-Nov | 0.95 | The record describes a secondary analysis of patient-reported outcomes from a Phase III randomized trial in non-small cell lung cancer. It evaluates the interpretability of quality-of-life score thresholds and does not report primary or key secondary time-to-event efficacy results (e.g., OS, PFS, HR). Furthermore, no drug intervention is specified; the analysis is on assessment methodology. | 待处理 |
| Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial.Ann Rheum Dis | PMID 35788492PMC9606523 | 2022-Nov | 0.85 | The study is a phase 3 randomized trial of a drug (upadacitinib) with original results, but it is not an oncology study (it is for ankylosing spondylitis, a rheumatic condition). Furthermore, the primary endpoint (ASAS40 response) is not a time-to-event endpoint like OS/PFS/DFS, and no Kaplan-Meier analysis or hazard ratio is indicated in the abstract. | 待处理 |
| Intravenous ferric derisomaltose versus saccharated ferric oxide for iron deficiency anemia associated with menorrhagia: a randomized, open-label, active-controlled, noninferiority study.Int J Hematol | PMID 35790696PMC9588477 | 2022-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of DBPR108 (prusogliptin) as an add-on to metformin therapy in patients with type 2 diabetes: A 24-week, multi-centre, randomized, double-blind, placebo-controlled, superiority, phase III clinical trial.Diabetes Obes Metab | PMID 35791646PMC9796963 | 2022-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Comparative efficacy and safety of two insulin aspart formulations (Rapilin and NovoRapid) when combined with metformin, for patients with diabetes mellitus: a multicenter, randomized, open-label, controlled clinical trial.Curr Med Res Opin | PMID 35833285无 PMCID | 2022-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study.Haemophilia | PMID 35905294PMC9796488 | 2022-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG Study.J Thorac Oncol | PMID 35932953无 PMCID | 2022-Nov | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Efficacy and safety of co-crystal of tramadol-celecoxib (CTC) in acute moderate-to-severe pain after abdominal hysterectomy: A randomized, double-blind, phase 3 trial (STARDOM2).Eur J Pain | PMID 35974668PMC9826359 | 2022-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial.Nat Med | PMID 36008722PMC9671806 | 2022-Nov | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Associations between urate levels and amyotrophic lateral sclerosis functional score with edaravone treatment: Post hoc analysis of studies MCI186-16, MCI186-17, and MCI186-19.Muscle Nerve | PMID 36054038无 PMCID | 2022-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Prehospital transdermal glyceryl trinitrate in patients with presumed acute stroke (MR ASAP): an ambulance-based, multicentre, randomised, open-label, blinded endpoint, phase 3 trial.Lancet Neurol | PMID 36058230无 PMCID | 2022-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |